SCHEMBL155606

SCHEMBL155606

ClCc1cc(Br)ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.39
HTR2A P28223 2/20 0.39
KCNH2 Q12809 2/20 0.39
ALDH1A1 P00352 2/20 0.37
PYCR1 P32322 1/20 0.36
CCR5 P51681 3/20 0.35
HPGD P15428 2/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP1A2 P05177 1/20 0.33
P2RX7 Q99572 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
HTR6 P50406 1/20 0.32
THRB P10828 1/20 0.32
HTT P42858 1/20 0.32
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299216 0.81 PYCR1 (0.47) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL29680819 0.81 SLC6A4 (0.39) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL844672 0.81 SLC6A4 (0.39) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL1561687 0.80 CYP2A6 (0.35) ALDH1A1PYCR1CCR5SMN1; SMN2CYP1A2
SCHEMBL154181 0.79 PTGDR2 (0.44) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL16036319 0.79 SLC6A4 (0.38) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL30609710 0.79 SLC6A4 (0.38) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL43286 0.79 GABRA1 (0.44) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL1758977 0.79 CCR5 (0.49) SLC6A4HTR2AKCNH2ALDH1A1PYCR1
SCHEMBL29426994 0.79 GABRA1 (0.44) SLC6A4HTR2AKCNH2ALDH1A1PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116332733-B Dapagliflozin middle Synthesis process of intermediate 江苏阿尔法药业股份有限公司 2025-02-11 CN disclosed
US-20240343740-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-10-17 US disclosed
CN-117658784-B Dapagliflozin middle Process for the preparation of intermediates 山东诚汇双达药业有限公司 2024-09-13 CN disclosed
EP-4341255-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS Eli Lilly and Company (US) 2024-03-27 EP disclosed
CN-117658784-A Preparation method of dapagliflozin intermediate 山东诚汇双达药业有限公司 2024-03-08 CN disclosed
CN-117355517-A Macrocyclic glucagon-like peptide 1 receptor agonists 伊莱利利公司 2024-01-05 CN disclosed
CN-116332733-A Synthesis process of dapagliflozin intermediate 江苏阿尔法药业股份有限公司 2023-06-27 CN disclosed
WO-2022246019-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2022-11-24 WO disclosed
CN-114773373-A Preparation method of engagliflozin key intermediate and engagliflozin impurity 浙江普洛家园药业有限公司 2022-07-22 CN disclosed
CN-109111463-B Method for producing aromatic compound DIC株式会社 2022-07-01 CN disclosed
US-20070073046-A1 Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-29 US disclosed
US-20070073046-A1 Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-29 US disclosed
WO-2007031548-A2 PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-22 WO disclosed
WO-2007031548-A2 PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-22 WO disclosed
CN-1829729-A Novel compounds TANABE SEIYAKU CO (JP) 2006-09-06 CN disclosed
EP-1651658-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2006-05-03 EP disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 US disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 WO disclosed
US-4400388-A Fungicidal 1-phenyl-2-(1,2,4-triazol-1-yl)-ethyl ethers BAYER AKTIENGESELLSCHAFT (DE) 1983-08-23 US disclosed
US-4327104-A FUNGICIDES AND BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1982-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 SLC6A4 1583/4885HTR2A 2962/4885KCNH2 1113/4885
US-20240343740-A1 MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS GLP1R, GCGR, GIPR SLC6A4 3233/4885HTR2A 857/4885KCNH2 790/4885
US-20070073046-A1 Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof UGGT1, B3GAT3, UGCG SLC6A4 3774/4885HTR2A 3643/4885KCNH2 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.